NeuroPace (NPCE) EBITDA (2020 - 2026)

NeuroPace's EBITDA history runs 7 years deep, the most recent figure standing at -$5.6 million for Q1 2026.

• On a quarterly basis, EBITDA fell 8.18% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$16.8 million, a 13.04% increase from a year earlier, with the FY2025 full-year figure at -$16.3 million, up 24.61% from the prior year.
• EBITDA fell to -$5.6 million in Q1 2026 per NPCE's latest filing, from -$1.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$1.8 million in Q4 2025 and bottomed at -$11.0 million in Q2 2022.
• The 5-year median for EBITDA is -$6.2 million (2024), against an average of -$6.6 million.
• Across the five-year window, EBITDA plunged 151.99% in 2022 and soared 51.63% in 2025, its largest moves.
• Year by year, EBITDA stood at -$9.9 million in 2022, then jumped by 48.77% to -$5.1 million in 2023, then advanced by 27.68% to -$3.7 million in 2024, then surged by 51.63% to -$1.8 million in 2025, then sank by 215.11% to -$5.6 million in 2026.
• Per Business Quant, the three latest NPCE EBITDA figures stand at -$5.6 million (Q1 2026), -$1.8 million (Q4 2025), and -$2.6 million (Q3 2025).